Items where authors include "Ashworth, A"
Article
Evans, RA, Leavy, OC, Richardson, M et al. (1003 more authors) (2022) Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. The Lancet Respiratory Medicine, 10 (8). pp. 761-775. ISSN 2213-2600
Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736
Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736
Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736
Escala-Garcia, M, Abraham, J, Andrulis, IL et al. (142 more authors) (2020) A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 11 (1). 312.
Danilenko, M, Stamp, E, Stocken, DD orcid.org/0000-0001-8031-1738 et al. (15 more authors) (2018) Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial. JAMA dermatology, 154 (8). pp. 913-921. ISSN 2168-6068
Cranston, A, Stocken, DD orcid.org/0000-0001-8031-1738, Stamp, E et al. (7 more authors) (2017) Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial. Trials, 18. 111. ISSN 1745-6215
Mateo, J, Carreira, S, Sandhu, S et al. (48 more authors) (2015) DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 373 (18). pp. 1697-1708. ISSN 0028-4793
Ghoussaini, M, Edwards, SL, Michailidou, K et al. (209 more authors) (2014) Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 5. 4999. ISSN 2041-1723
Herrera-Abreu, MT, Pearson, A, Campbell, J et al. (4 more authors) (2013) Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discovery, 3 (9). 1058 - 1071. ISSN 2159-8274
Garcia-Closas, M, Couch, FJ, Lindstrom, S et al. (271 more authors) (2013) Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics, 45 (4). pp. 392-398. ISSN 1061-4036
Bojesen, SE, Pooley, KA, Johnatty, SE et al. (442 more authors) (2013) Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 45 (4). pp. 371-384. ISSN 1061-4036
Ghoussaini, M, Fletcher, O, Michailidou, K et al. (184 more authors) (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 44 (3). pp. 312-318. ISSN 1061-4036